Processa Pharmaceuticals Inc expected to post a loss of 20  cents a share - Earnings Preview

Processa Pharmaceuticals

09/08/2022 03:03

* Processa Pharmaceuticals Inc  PCSA.OQ   PCSA.O  is
expected
to show no change in quarterly revenue when it reports 
results on August 11. 
    * ​Refinitiv's mean analyst estimate for Processa
Pharmaceuticals
Inc is for a loss of 20 cents per share. For the same quarter
last year, the company reported a loss of 20 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Processa
Pharmaceuticals Inc is $13​, above​ its last closing price
of $3.14. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.21       -0.21      -0.20     Beat    6.2
 Dec. 31 2022  -0.18       -0.19      -0.21     Missed  -10.5
 Sep. 30 2021  -0.18       -0.18      -0.19     Missed  -3.6​
 Jun. 30 2021  -0.14       -0.14      -0.20     Missed  -39.5
 ​​Mar.        -0.10       -0.10      -0.14     Missed  -33.3
 31 2021                                                
 Dec. 31 2020  -0.16       -0.35      -1.69     Missed  -376.1
                                                        ​
 Sep. 30 2020  -0.16       -0.16      -0.55     Missed  -243.7
 This summary was machine generated August 9 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated